Literature DB >> 4916019

Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate.

C E Blackard, R P Doe, G T Mellinger, D P Byar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4916019     DOI: 10.1002/1097-0142(197008)26:2<249::aid-cncr2820260202>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  14 in total

1.  Can drug therapy alter the natural course of peripheral vascular disease?: a review.

Authors:  C A Clyne
Journal:  Proc R Soc Med       Date:  1977

2.  The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women.

Authors:  S G Thompson; T W Meade; G Greenberg
Journal:  J Epidemiol Community Health       Date:  1989-06       Impact factor: 3.710

3.  Five-year clinical follow-up of prostatic cancer patients treated with fosfestrol and bromocriptine.

Authors:  L Jeromin; J Wiśniewski; M Rozniecki; Z Janiak; J Borkiewicz
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

4.  Effect of testosterone cypionate on postexercise ST segment depression.

Authors:  M D Jaffe
Journal:  Br Heart J       Date:  1977-11

Review 5.  Current concepts in the management of carcinoma of the prostate gland.

Authors:  E M Meares
Journal:  Calif Med       Date:  1972-12

6.  Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group.

Authors:  D P Byar
Journal:  Bull N Y Acad Med       Date:  1972-06

7.  Prostatic carcinoma in Nigeria: a 10-year retrospective study.

Authors:  F N Udeh
Journal:  Int Urol Nephrol       Date:  1981       Impact factor: 2.370

Review 8.  Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.

Authors:  R N Brogden; S P Clissold
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

9.  Estrogen in patients with prostatic cancer. An assessment of the risks and benefits.

Authors:  P Henriksson
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

Review 10.  Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  M G Harris; S G Coleman; D Faulds; P Chrisp
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.